Technical Analysis for AEZS - AEterna Zentaris Inc.

Grade Last Price % Change Price Change
grade C 4.0 1.01% 0.04
AEZS closed up 1.01 percent on Monday, March 18, 2019, on 84 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical AEZS trend table...

Date Alert Name Type % Chg
Mar 18 20 DMA Support Bullish 0.00%
Mar 18 MACD Bullish Centerline Cross Bullish 0.00%
Mar 18 MACD Bullish Signal Line Cross Bullish 0.00%
Mar 18 Doji - Bearish? Reversal 0.00%
Mar 15 20 DMA Support Bullish 1.01%
Mar 15 50 DMA Support Bullish 1.01%
Mar 14 Narrow Range Bar Range Contraction 0.50%
Mar 14 NR7 Range Contraction 0.50%
Mar 14 Inside Day Range Contraction 0.50%
Mar 13 Crossed Above 20 DMA Bullish 0.00%

Older signals for AEZS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan. It markets Cetrotide, a luteinizing hormone-releasing hormone antagonist treatment for in vitro fertilization. The company's product pipeline includes AEZS-108, which is in Phase III clinical trial for the treatment of endometrial cancer, as well as in Phase II clinical trial to treat triple-negative breast, ovarian, castration and taxane resistant prostate, and refractory bladder cancers; and AEZS-130, an oral diagnostic test that has completed Phase III clinical trial for adult growth hormone deficiency, as well as in Phase IIA clinical trial for the treatment of cancer-induced cachexia. Its product pipeline also comprise Ozarelix, which is in Phase II clinical trial for the treatment of prostate cancer; Perifosine that is in Phase I/II clinical trials for the treatment of neuroblastoma, glioma, and pediatric solid tumors; and AEZS-112 an oral anticancer agent, which has completed Phase I clinical trial for the treatment of solid tumors and lymphoma. In addition, the company's products in preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate for the treatment of prostate cancer; AEZS-129, 134, and 136 PI3K/Erk inhibitors for oncology; and AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.
Chemistry Biopharmaceutical Cancer Treatment Of Cancer Solid Tumors Oncology Prostate Cancer Lymphoma Peptides Neuroblastoma Glioma Treatment Of Prostate Cancer Anthracyclines Gnrh Antagonists Endometrial Cancer In Vitro Fertilization Ozarelix
Is AEZS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.39
52 Week Low 1.12
Average Volume 342,897
200-Day Moving Average 2.56
50-Day Moving Average 3.8558
20-Day Moving Average 3.9115
10-Day Moving Average 3.802
Average True Range 0.2169
ADX 16.34
+DI 23.853
-DI 18.9552
Chandelier Exit (Long, 3 ATRs ) 3.7393
Chandelier Exit (Short, 3 ATRs ) 4.1507
Upper Bollinger Band 4.2595
Lower Bollinger Band 3.5635
Percent B (%b) 0.63
BandWidth 17.793685
MACD Line 0.0089
MACD Signal Line 0.0027
MACD Histogram 0.0061
Fundamentals Value
Market Cap 64.45 Million
Num Shares 16.1 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -2.34
Price-to-Sales 28.12
Price-to-Book 6.12
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.36
Resistance 3 (R3) 4.36 4.25 4.30
Resistance 2 (R2) 4.25 4.15 4.25 4.28
Resistance 1 (R1) 4.12 4.10 4.19 4.12 4.26
Pivot Point 4.01 4.01 4.04 4.01 4.01
Support 1 (S1) 3.88 3.91 3.95 3.88 3.74
Support 2 (S2) 3.77 3.86 3.77 3.72
Support 3 (S3) 3.64 3.77 3.70
Support 4 (S4) 3.64